ADGRF5 and colitis: Finally, using these novel ADGRF5 agonists, we demonstrated their potent anti-inflammatory effects <i>in vivo</i>, showing that ADGRF5 activation ameliorates experimental colitis, as evidenced by reduced macroscopic damage scores and improved colon architecture.